Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies

Introduction: Patients (pts) with hematological malignancies (HMs) are at increased risk for severe COVID19 infection and death (Grivas, 2021). Currently, vaccination represents the most effective prevention approach. HM pts have been shown to have lower immune responses to COVID19 vaccine, particul...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Ning, Jain, Akriti G, Tan, Elaine S, Ball, Somedeb, Whiting, Junmin, Gaballa, Sameh, Isenalumhe, Leidy, Bello, Celeste, Saeed, Hayder, Shah, Bijal D., Locke, Frederick L., Chavez, Julio C., Lancet, Jeffrey E., Sokol, Lubomir, Pinilla Ibarz, Javier, Giuliano, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
627.Aggressive Lymphomas: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701761/
http://dx.doi.org/10.1182/blood-2021-150465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701761/
http://dx.doi.org/10.1182/blood-2021-150465

Ejemplares similares